JPMorgan raised the firm’s price target on Dyne Therapeutics to $43 from $39 and keeps an Overweight rating on the shares following a model update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics participates in a conference call with JPMorgan
- Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
- Dyne announces new Pompe disease data showing potential of FORCE platform
- Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
- Dyne Therapeutics to Present at Jefferies Global Healthcare Conference